- $394.95m
- -$58.86m
- $97.67m
- 51
- 30
- 45
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.8 | ||
| Price to Tang. Book | 0.84 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.64% | ||
| Return on Equity | -23.72% | ||
| Operating Margin | -188.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 32.19 | 55.89 | 81.63 | 97.67 | 83.8 | 98.63 | 44.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 15th, 2020
- Public Since
- February 23rd, 2021
- No. of Shareholders
- 247
- No. of Employees
- 451
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 188,071,546
- Address
- C/O Somalogic, BOULDER, 80301
- Web
- https://somalogic.com/
- Phone
- +1 3036259000
- Contact
- Lauren Glaser
- Auditors
- Ernst & Young LLP
Upcoming Events for SLGC
Q1 2024 Somalogic Inc Earnings Release
Somalogic Inc Annual Shareholders Meeting
Similar to SLGC
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Somalogic share price?
As of Today at 18:20 UTC, shares in Somalogic are trading at $2.10. This share price information is delayed by 15 minutes.
How has the Somalogic share price performed this year?
Shares in Somalogic last closed at $2.10 and the price had moved by -19.54% over the past 365 days. In terms of relative price strength the Somalogic share price has underperformed the S&P500 Index by -33.28% over the past year.
What are the analyst and broker recommendations for Somalogic?
The overall consensus recommendation for Somalogic is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Somalogic dividend yield?
Somalogic does not currently pay a dividend.
Does Somalogic pay a dividend?
Somalogic does not currently pay a dividend.
When does Somalogic next pay dividends?
Somalogic does not currently pay a dividend.
How do I buy Somalogic shares?
To buy shares in Somalogic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Somalogic?
As of the previous close price of $2.10, shares in Somalogic had a market capitalisation of $394.95m.
Where are Somalogic shares listed?
Here are the trading details for Somalogic:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SLGC
What kind of share is Somalogic?
Based on an overall assessment of its quality, value and momentum Somalogic is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Somalogic share price forecast for 2024?
The analyst consensus target price for shares in Somalogic is $3.93. That is 87.14% above the last closing price of $2.10.
Analysts covering Somalogic currently have a consensus Earnings Per Share (EPS) forecast of -$0.59 for the next financial year.
Find out moreWhat is the trend in the Somalogic share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Somalogic. Over the past six months, its share price has underperformed the S&P500 Index by -9.57%.
As of the last closing price of $2.10, shares in Somalogic were trading -14.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Somalogic PE Ratio?
The Somalogic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Somalogic?
We do not have data on Somalogic's directors